Stock Market News
Futura Medical's successful erectile dysfunction trials boost share price
(WebFG News) - Futura Medical announced on Wednesday that a pharmacokinetic study of MED2002, the company's gel-based erectile dysfunction (ED) treatment, has yielded positive results.
The study, which commenced in November, evaluated the doses of 0.2%, 0.4%, 0.6% and 0.8% of the gel's active ingredient glyceryl trinitrate (GTN) to assess the viability of different dosages for the treatment of ED.
Higher dosages were found to have caused higher concentrations of the ingredient in the bloodstream, supporting the theory that higher dosages will improve product efficacy.
High doses of the ingredient were "well tolerated" by the subjects of the study, with only mild incidences such as headaches, shown to occur in less than 2% of intercourse attempts, being recorded.
GTN demonstrated a rapid rate of absorption in the study and was directed in the bloodstream just five minutes after the application of the gel.
Futura Medical said this is a key feature of the product as potential competitor products like Viagra and Cialis are taken orally and can take as long as half an hour, an hour or even longer to take effect.
James Barder, chief executive of Futura Medical, said: "We are delighted to report the excellent data from our latest PK study for MED2002. The results show the effectiveness of our DermaSys transdermal technology and demonstrate the potential of MED2002 as a rapid and safe treatment option for erectile dysfunction."
Phase III studies for MED2002 are currently being planned by Futura Medical.
As of 1039 BST, Futura Medical's shares were up 7.69% at 35.00p.
The study, which commenced in November, evaluated the doses of 0.2%, 0.4%, 0.6% and 0.8% of the gel's active ingredient glyceryl trinitrate (GTN) to assess the viability of different dosages for the treatment of ED.
Higher dosages were found to have caused higher concentrations of the ingredient in the bloodstream, supporting the theory that higher dosages will improve product efficacy.
High doses of the ingredient were "well tolerated" by the subjects of the study, with only mild incidences such as headaches, shown to occur in less than 2% of intercourse attempts, being recorded.
GTN demonstrated a rapid rate of absorption in the study and was directed in the bloodstream just five minutes after the application of the gel.
Futura Medical said this is a key feature of the product as potential competitor products like Viagra and Cialis are taken orally and can take as long as half an hour, an hour or even longer to take effect.
James Barder, chief executive of Futura Medical, said: "We are delighted to report the excellent data from our latest PK study for MED2002. The results show the effectiveness of our DermaSys transdermal technology and demonstrate the potential of MED2002 as a rapid and safe treatment option for erectile dysfunction."
Phase III studies for MED2002 are currently being planned by Futura Medical.
As of 1039 BST, Futura Medical's shares were up 7.69% at 35.00p.
Related share prices |
---|
Futura Medical (FUM) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price